Market Overview: Gastric Cancer   27-slide PPT PowerPoint presentation (PPTX)
$299.00

Market Overview: Gastric Cancer (27-slide PPT PowerPoint presentation (PPTX)) Preview Image Market Overview: Gastric Cancer (27-slide PPT PowerPoint presentation (PPTX)) Preview Image Market Overview: Gastric Cancer (27-slide PPT PowerPoint presentation (PPTX)) Preview Image Market Overview: Gastric Cancer (27-slide PPT PowerPoint presentation (PPTX)) Preview Image Market Overview: Gastric Cancer (27-slide PPT PowerPoint presentation (PPTX)) Preview Image Market Overview: Gastric Cancer (27-slide PPT PowerPoint presentation (PPTX)) Preview Image Log in to unlock full preview.
Loading preview images...
Arrow   Unlock all 9 preview images:   Login Register

Market Overview: Gastric Cancer (PowerPoint PPTX)

PowerPoint (PPTX) 27 Slides

$299.00

Add to Cart
  


Immediate download
Fully editable PowerPoint
Free lifetime updates

BENEFITS OF DOCUMENT

  1. In 2015, major-market sales totaled $1.2 billion for gastric and gastroesophageal

DESCRIPTION

This product (Market Overview: Gastric Cancer) is a 27-slide PPT PowerPoint presentation (PPTX), which you can download immediately upon purchase.

In 2015, major-market sales totaled $1.2 billion for gastric and gastroesophageal junction (GEJ) adenocarcinoma. We expect that major-market sales will rapidly increase over the forecast period, totaling almost $9.5 billion in 2025. This growth will be predominantly fuelled by the approval of seven agents in the indication, and also by Cyramza (Eli Lilly's ramucirumab).

The entry of three PD-1/PD-L1 inhibitors into the gastric and GEJ adenocarcinoma market (Merck & Co.'s Keytruda [pembrolizumab], Bristol Myers-Squibb/Ono Pharmaceutical's Opdivo [nivolumab], and Merck KGaA/Pfizer's avelumab) will significantly drive growth during the forecast period. We also forecast the approval of Yervoy (Bristol Myers-Squibb/Ono Pharmaceutical's ipilimumumab) to be used in conjunction with Opdivo. In addition, we anticipate the launch of a next generation HER2-targeting therapy (Roche/Genentech/Chugai's Perjeta [pertuzumab]), a cancer 'stemness' inhibitor (Boston Biomedical's napabucasin), and a MMP-9 inhibitor (Gilead Sciences's GS-5745). Collectively, these agents will contribute 80% of total sales in the gastric and GEJ adenocarcinoma in 2025.


Introduction
Key Findings
Market Share of Gastric Cancer Drug Classes in 2015 and 2025
Market SWOT Analysis
Etiology and Pathophysiology
Key Findings
Expert Insight
Pathophysiology
Anatomy
Subtypes
Staging and Classification
Key Pathways and Drug Targets
Market Outlook
Key Findings
Expert Insight
Market Overview
Market Drivers and Constraints
What Factors Are Driving the Market?
What Factors Are Constraining the Market?

Got a question about the product? Email us at support@flevy.com or ask the author directly by using the "Ask the Author a Question" form. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Best Practices in Healthcare, Cancer PowerPoint Slides: Market Overview: Gastric Cancer PowerPoint (PPTX) Presentation, pharmzolgas


$299.00

Add to Cart
  

ABOUT THE AUTHOR

Author: pharmzolgas
Additional documents from author: 3

Ask the Author a Question

Must be logged in

Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.




Trusted by over 10,000+ Client Organizations
Since 2012, we have provided best practices to over 10,000 businesses and organizations of all sizes, from startups and small businesses to the Fortune 100, in over 130 countries.
AT&T GE Cisco Intel IBM Coke Dell Toyota HP Nike Samsung Microsoft Astrazeneca JP Morgan KPMG Walgreens Walmart 3M Kaiser Oracle SAP Google E&Y Volvo Bosch Merck Fedex Shell Amgen Eli Lilly Roche AIG Abbott Amazon PwC T-Mobile Broadcom Bayer Pearson Titleist ConEd Pfizer NTT Data Schwab




Read Customer Testimonials


Your Recently Viewed Documents


Customers Also Like These Documents

Related Management Topics


Healthcare Cancer Integrated Financial Model Value Chain Analysis

Download our FREE Strategy & Transformation Framework Templates

Download our free compilation of 50+ Strategy & Transformation slides and templates. Frameworks include McKinsey 7-S Strategy Model, Balanced Scorecard, Disruptive Innovation, BCG Experience Curve, and many more.